Boston Scientific (NYSE:BSX) reported strong positive results from its pivotal FRACTURE IDE trial for the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The trial assessed safety and ...
Original Image Link
Source:finance.yahoo.com
Original Image Link
Source:finance.yahoo.com
Posted: 2026-06-02 04:34:00

















